This Saturday:

A woman who lost part of her vision while an insurance company reviewed her paperwork. A model built on a flat monthly fee that now has 1.4 million members. And the FDA pharmacologist who spent 17 months refusing to approve a drug already being marketed in 46 countries.

Sit back, relax, and enjoy the reading.

Ocean McIntyre was 34 when she started losing her vision.

Pressure was building inside her skull, slowly crushing her optic nerve. Her doctor knew what was happening. The fix required a specialist, a neuro-ophthalmologist.

The first emergency was medical. The second one was paperwork.

She waited three months.

By the time the insurance company said yes, the window for preserving her vision had closed.

Her specialist told her directly: if they had gotten to her sooner, things would have been different.

Before the wait, she had been a tattoo artist, a private pilot, a research assistant at NASA's Jet Propulsion Laboratory. She was 34. The damage is permanent.

She is now 51, legally blind, and struggling to find work. "I have no peripheral vision at all. It's like looking through a straw, and what I see is semi-sharp in one eye and completely blurry in the other," she said. "I fall and trip over things all the time, even inside the house. Obviously, I'm not flying planes or driving cars anymore."

Prior authorization requires patients to get insurer approval before seeing certain specialists or starting certain treatments. The stated purpose is cost control. Someone at the insurance company reviewed Ocean's case and ran the process correctly.

A 34-year-old woman, in the middle of her life, lost part of her sight because a form took three months to move. The system did not malfunction. It processed her correctly. Her vision was the cost that never appeared in the calculation. The paperwork is clean. The process is intact.

The specialist who finally reached her told her what had happened. Someone, beyond the process, still looked at her as a patient. The complete loss of her vision did not happen. That part was not the system's doing.

The system ran the numbers. No one put that in the denial letter.

There are millions of Ocean McIntyres. Most of them never find out why the window closed.

In 2017, there were a few hundred Direct Primary Care practices in the United States.

By 2025, there were 2,688, operating in all 50 states, serving 1.4 million members. DPC membership grew 837% per capita over that period. More than 7,200 employers now offer it as a benefit.

The model is straightforward. Patients pay a flat monthly fee directly to their doctor. No claims. No prior authorization. No paperwork between the diagnosis and the treatment.

Hint Health, which tracks the DPC market, released its 2026 report with a line that would have sounded like an exaggeration five years ago: DPC has moved from niche alternative to national healthcare infrastructure.

The full Hint Health 2026 report breaks down adoption by state, employer size, and patient demographics. The pattern holds across all of them: the practices growing fastest are the ones that removed everything standing between the doctor and the patient.

The people leaving the traditional system are not making a political statement. They are solving a problem the system left open. When paperwork outlasts the treatment window, patients stop waiting for the process to change and start looking for someone who operates without it.

DPC practices grow because doctors made the same calculation. They did not want to process charts. They wanted to treat people. The patients who found them were looking for the same thing. Both sides of the appointment arrived at the same room for the same reason: the current model had stopped seeing either of them clearly.

A DPC doctor would have seen Ocean McIntyre without a form, without a case number, without three months on a waiting list. The model works because the incentive is different. There is no insurance company in the room. There is a doctor who chose this because they wanted to know their patients, not process them.

The doctor who answers the phone chose to be there.

In September 1960, Frances Kelsey had been at the FDA for one month.

Her second assignment: review an application for a sleeping pill called Kevadon. Already approved in 46 countries. Already marketed across Europe and Australia as safe for pregnant women with morning sickness.

Richardson-Merrell, the company selling it, was confident it would sail through.

Kelsey read the application and had questions. There was evidence of peripheral neuropathy, nerve damage, in patients on the drug long-term. The application did not address what it would do in pregnancy.

She sent the company back for more data.

They came to her office.

Then they came again.

Over 18 months, company representatives showed up approximately 50 times. They wrote to her supervisors calling her unreasonable. They insisted the science was settled.

She kept asking for evidence.

In November 1961, a German newspaper reported that a drug called Thalidomide, the same compound under a different trade name, appeared to be causing severe birth defects in Europe. Babies were being born with malformed or missing limbs.

More than 10,000 children. Europe. Australia. Canada.

Richardson-Merrell withdrew the application in March 1962.

In the United States, about 40 to 50 babies were affected, most from clinical trials that had distributed the drug before the approval was denied.

President Kennedy gave Kelsey the Distinguished Federal Civilian Service Award that August. It was the highest honor a civilian employee could receive.

She had spent 17 months being told she was being difficult.

She was being a scientist.

Kelsey was not working from instinct. She had a question the data had not yet answered, and she refused to sign until it could. Every time Richardson-Merrell returned to her office, she asked it again.

The question was not complicated. What does this drug do to a fetus? Nobody could show her the answer. So she kept the door closed.

Studies open doors. The evidence that cannot yet be shown, when someone pays attention to it, keeps the wrong ones shut. Kelsey paid attention for 17 months. Forty to fifty American children were affected by thalidomide, compared to more than 10,000 in Europe. That is not a coincidence. It is the result of one person deciding that the small voice asking for more evidence was worth listening to.

The difference was not efficiency. It was what each process was designed to protect.

The 2026 healthcare system has not yet answered which of those two it is running.

See you next Saturday.